Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06937099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
June 26, 2025
Completion date
May 31, 2028
Enrollment
290 (estimated)
Sites
183

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, obesity or overweight